



Nova Eye Medical's iTrack™ and Molteno3® Glaucoma Technologies to Feature at the American Academy of Ophthalmology (AAO) 2020 Virtual Meeting

Fremont, California, 13 November 2020 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to report that the Company's proprietary iTrack™ canaloplasty microcatheter technology for minimally invasive glaucoma surgery (MIGS) and the Molteno3® glaucoma drainage device will feature as part of the Skills Transfer Course Program at the virtual meeting of the American Academy of Ophthalmology (AAO), November 13-15, 2020.

The AAO is the world's largest association of eye physicians and surgeons, comprising a global community of 32,000 medical doctors. The AAO Skills Transfer Course Program is hosted annually and forms part of the Academy's Continuing Medical Education (CME) program.

"We are thrilled that our glaucoma technologies will be showcased to AAO delegates via the Academy's Skills Transfer Course Program. This program provides an interactive educational forum through which ophthalmologists can finetune their surgical skills and best practice technique," commented Mr. Joe Bankovich, President of Nova Eye Medical.

Details for the AAO 2020 Skills Transfer Courses featuring iTrack™ and Molteno3® are outlined below:

(iTrack™)

"MIGS: Devices and Incisional Techniques"

Session: LAB124V Virtual Meeting Live Broadcast

Sunday, 8:35AM - 9:20AM PST

<https://aaommg.apprvisor.org/apsSession.cfm?id=LAB124V>

(Molteno3®)

"Glaucoma Tube Shunts to Equatorial Plate Reservoir"

Session: LAB132A

Available On Demand

<https://aaommg.apprvisor.org/apsSession.cfm?id=LAB132A>



ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe or complex glaucoma. It also offers the benefit of a simplified and faster surgical profile. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com

Media enquires:

Kate Hunt
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

Investor enquires:

Dr. Tom Duthy
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com